2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版)

2021-06-20 德国妇科肿瘤小组 Breast Care (Basel). 2021 Jun;16(3):228-235.

2021年7月,德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版。主要内容涉及乳腺癌一级预防,风险评估和预防,乳腺癌的诊断,病理临床治疗等。

中文标题:

2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版)

英文标题:

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021

发布机构:

德国妇科肿瘤小组

发布日期:

2021-06-20

简要介绍:

2021年7月,德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版。主要内容涉及乳腺癌一级预防,风险评估和预防,乳腺癌的诊断,病理临床治疗等。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=b12271c0021380a5, title=2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版), enTitle=AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021, guiderFrom=Breast Care (Basel). 2021 Jun;16(3):228-235., authorId=0, author=, summary=2021年7月,德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版。主要内容涉及乳腺癌一级预防,风险评估和预防,乳腺癌的诊断,病理临床治疗等。, cover=https://img.medsci.cn/2021728/1627484688447_2020535.jpg, journalId=0, articlesId=null, associationId=1692, associationName=德国妇科肿瘤小组, associationIntro=, copyright=0, guiderPublishedTime=Sun Jun 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年7月,德国妇科肿瘤小组(AGO)发布了早期乳腺癌患者的诊断和治疗更新版。主要内容涉及乳腺癌一级预防,风险评估和预防,乳腺癌的诊断,病理临床治疗等。</p> </div> </div> </div>, tagList=[TagDto(tagId=5047, tagName=转移性乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5047, guiderKeyword=转移性乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8901, appHits=91, showAppHits=0, pcHits=638, showPcHits=8806, likes=0, shares=10, comments=3, approvalStatus=1, publishedTime=Wed Jul 28 23:26:01 CST 2021, publishedTimeString=2021-06-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Jul 28 23:04:56 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 02:12:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版).pdf)])
2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版).pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1012712, encodeId=51d11012e12e2, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe05588514, createdName=ms2000002012367634, createdTime=Mon Aug 30 02:36:22 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005348, encodeId=e7a51005348b6, content=希望能更细致点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Thu Aug 05 13:22:00 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005045, encodeId=9a9c1005045ef, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:09:44 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2021-08-30 ms2000002012367634

    下载学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1012712, encodeId=51d11012e12e2, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe05588514, createdName=ms2000002012367634, createdTime=Mon Aug 30 02:36:22 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005348, encodeId=e7a51005348b6, content=希望能更细致点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Thu Aug 05 13:22:00 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005045, encodeId=9a9c1005045ef, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:09:44 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2021-08-05 凉纪之

    希望能更细致点

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1012712, encodeId=51d11012e12e2, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe05588514, createdName=ms2000002012367634, createdTime=Mon Aug 30 02:36:22 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005348, encodeId=e7a51005348b6, content=希望能更细致点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Thu Aug 05 13:22:00 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005045, encodeId=9a9c1005045ef, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:09:44 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2021-08-04 ms9000001873897494

    受益匪浅

    0

拓展阅读

2018 AGO建议:晚期和转移性乳腺癌的诊断和治疗(更新版)

德国妇科肿瘤小组(AGO,German Gynecological Oncology Group) · 2018-07-13

复发/转移性乳腺癌标志物临床应用专家共识(2019年版)

中国抗癌协会(Chinese Anti-cancer Association) · 2019-10-30

2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2021-10-13

2022 ASCO 指南更新:转移性乳腺癌全身治疗的生物标志物

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2022-06-27

ASCO指南更新:生物标志物指导转移性乳腺癌的系统性治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2022-06-27